Charlottesville, VA and Athens, Greece.
Biovista began work today on two internal programs aimed to reposition marketed drugs or drugs in Phase II/III in Macular Degeneration and CNS. Biovista has already identified a number of candidates with the requisite biological plausibility that are also unencumbered by prior patent filings or prior art. The Company is proceeding with validation studies and will announce relevant patent filings in due course.